Newsletter

Medisafe 1 Technologies (Public, OTC: MFTH) is seeking to effectively prevent the unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.  Founded in July 2009, Medisafe is  a development stage company focusing on the development and sale of medical assemblies and protectors. The company has licensed the technology and received a patent for a medical assembly and protector. The principle features of the design include the protector which fits over a proportion of the medicine assembly, the protector which includes a bar code and locking element, an electrically operated device to control the locking element, and a connection to a bar code reader. 

 

 

Vision

 

Medisafe's product is the first U.S. Patented Technology that focuses on eliminating the administration of incorrect medicinal substances by Hypodermic Needle.  

Their goal is:

"Administering the Right Drug with the Right Dose to the Right Patient At the Right Time"

 

Product

 

protector device with locking mechanism that ensures that the substance is only released from the hypodermic needle after positive technology-based pre-matching with the specific patient, using barcode technology

Direct annual cost of preventable drug related mortality & morbidity $177.4 billion

Annual potential market in the U.S.could be $1.4 billion

 

For more information, visit the company website at http://www.medisafe1.com/home.html.

 

Symbol

Price

Change

MFTH.OB

0.3050

+0.0050

 

 

The State of Israel's Nationwide Blood Banks Commence Discussions to Adopt Medisafe 1 Technologies Corporation's Pre-Matching Drug Safety Administration Technology

 

JERUSALEM, January 18, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB:MFTH.ob - News), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has initiated discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversea the entire Nation's Blood Banks.

Discussions are with Israel's Magen David Adom, or Red Shield of David. This organization is the international equivalent of the Red Cross or Red Crescent and Magen David Adom are responsible for and overlook all of the national blood banks that provide blood to Israeli hospitals and other Medical Clinics in Israel.

Discussions are to focus on implementing Medisafe 1 Technology's patented pre-matching safety locking device on blood bags and vials. Using the technology, a barcode reader would need to electronically confirm that a particular patient was being administered the appropriate and correct blood type prior to the release of the blood from the vial.

"Improper infusion of blood caused by human error is an avoidable cause of death," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "Applying the concepts behind our patented pre-matching safety locking device technology to infusion bags, and blood vials can contribute to a reduction in the number of preventable deaths in hospitals."

"We are hopeful that the future implementation of the technology in Israel Blood Banks if approved can lead to its implementation in other countries. We have similarly initiated discussions with blood banks in the U nited States."

Medisafe 1 Technologies has already developed its locking device technology for syringes in hospitals. It is estimated that the application of the technology for infusion bags will be ready for demonstration within three months time.

 

 

Medisafe 1 Technologies Receives Endorsement for National Implementation From Israel's Pharmaceuticals Administration

 

JERUSALEM, January 10, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB:MFTH.ob - News), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has received endorsement for the national implementation of its barcoded syringe locking device, from Israel's Pharmaceuticals Administration.

The endorsement was received as the final of a series of meetings with Health Ministry officials. The latest meeting was conducted with the Chief Technical Officer of Israel's Pharmaceuticals Administration.

The previous meeting was held with Directors of Israel's Health Ministry including Deputy Minister Yaakov Litzman. The Health Ministry portfolio is officially held by Prime Minister Benjamin Netanyahu.

Members of the Pharmaceuticals Administration were particularly pleased with the lifesaving benefits of the syringe-locking device, as well as the locking device's ability to reduce theft by individuals wishing to intentionally use or sell prescription medications.

Following official endorsement, Medisafe 1 Technologies has been in discussion with a leading Israeli pharmaceuticals company to partner in streamlining the production process the introduction of the device at Israeli Medical Centers.

The pharmaceuticals company also expressed interest in advancing the development of Medisafe 1 Technologies' proposed locking-device for blood transfusion bags.

"Officials across Israel's health system have been duly impressed with the potential of our locking devices to reduce hospital injuries and save lives, thus reducing the legal and insurance related costs associated with running hospitals," said, Jacob Elhadad, CEO of Medisafe 1 Technologies.

"We are now in serious discussions with the companies that will aid us toward full commercialization of our products."